Bristol-Myers signs exclusive option deal to buy Galecto and new Galectin-3 inhibitor
Galecto’s TD139 is currently in Phase I development and is designed to treat idiopathic pulmonary fibrosis (IPF) and other pulmonary fibrotic conditions. TD139 is a highly potent, specific
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.